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Childhood absence epilepsy (CAE) accounts for 10% to 12% of epilepsy in children under 16 years of age. We screened for mutations in
the GABAA receptor (GABAR) b3 subunit gene (GABRB3) in 48 probands and families with remitting CAE. We found that four out of 48
families (8%) had mutations in GABRB3. One heterozygous missense mutation (P11S) in exon 1a segregated with four CAE-affected per-
sons in onemultiplex, two-generationMexican family. P11S was also found in a singleton fromMexico. Another heterozygousmissense
mutation (S15F) was present in a singleton fromHonduras. An exon 2 heterozygous missense mutation (G32R) was present in two CAE-
affected persons and two persons affected with EEG-recorded spike and/or sharp wave in a two-generation Honduran family. All muta-
tions were absent in 630 controls.We studied functions and possible pathogenicity by expressingmutations in HeLa cells with the use of
Western blots and an in vitro translation and translocation system. Expression levels did not differ from those of controls, but all mu-
tations showed hyperglycosylation in the in vitro translation and translocation system with canine microsomes. Functional analysis of
human GABAA receptors (a1b3-v2g2S, a1b3-v2[P11S]g2S, a1b3-v2[S15F]g2S, and a1b3-v2[G32R]g2S) transiently expressed in HEK293T
cells with the use of rapid agonist application showed that each amino acid transversion in the b3-v2 subunit (P11S, S15F, and G32R)
reduced GABA-evoked current density fromwhole cells. Mutated b3 subunit protein could thus cause absence seizures through a gain in
glycosylation of mutated exon 1a and exon 2, affectingmaturation and trafﬁcking of GABAR from endoplasmic reticulum to cell surface
and resulting in reduced GABA-evoked currents.Introduction
Childhood absence epilepsy (CAE [ECA1 (MIM 600131),
ECA2 (MIM 607681), ECA3 (MIM 607682), ECA4 (MIM
611136)]),1–4 a common idiopathic generalized epilepsy
(EIG [MIM 600669]), accounts for 10% to 12% of epilepsy
in children under 16 years of age according to prospective
community-based epidemiologic studies.5,6 Absence is
characterized by frequent brief loss of consciousness lasting
3 to 10 s and occurring up to about 200 attacks per day. The
electroencephalograph shows bilateral, symmetrical, syn-
chronous, 3–4 Hz spike-and-wave bursts during absence
seizures.7 CAE appears more frequently in girls,8,9 and
when present as the sole phenotype, CAE has better prog-
nosis10 and remits in 95%of cases in Loiseau’s report.11His-
torically, a strong genetic contribution to the spike-wave
traits of CAE has been supported by 74% concordance for
monozygotic twins and 27% concordance for dizygotic
twins.12 Metrakos and Metrakos showed that siblings and
offspring had (a) 50% risk of inheriting the 3Hz spike-
wave trait, (b) 35% risk of expressing the EEG trait in theirThe Amlifetime, and (c) 12% risk for tonic-clonic seizures and 8%
risk for absences.13–15 These family and twin studies sup-
port the concept of a major gene interacting with addi-
tional genetic and environmental factors in CAE.
In 1999, Feucht et al.16 used aMonte Carlo version of the
multiallele Transmission Disequilibrium Test to show pos-
sible association between GABRB3 (MIM 137192) and CAE
in 50 Austrians. Urak et al.17 then replicated signiﬁcant
association between 45 CAE patients and 13 SNPs located
between the exon 1a promoter and the beginning of in-
tron 3 within GABRB3. Reporter-gene assays in NT2 cells
(human neuronal-like cell lines) showed lower transcrip-
tional activity of the disease-associated GABRB3 promoter
haplotype. We screened for mutations in GABRB3 in fami-
lies ascertained through a proband with remitting pykno-
leptic CAE because of the ﬁndings in the above studies
by Feucht et al.16 and Urak et al.,17 because typical and
atypical absence attacks are present in Angelman syn-
drome patients whose chromosome 15q11–13 deletion in-
cludes GABRB3,18 and because heterozygous and homozy-
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attacks with EEG characteristics and pharmacological re-
sponses similar to human absence seizures.19,20
Subjects and Methods
Family Material
We ascertained 48 families, through probands with remitting
pyknoleptic childhood absence epilepsy, from Mexico City and
Hermosillo,Mexico; Tegucigalpa,Honduras; andSanMiguel, El Sal-
vador (See Table 1 for inclusion and exclusion criteria). Initial diag-
nosis was made by neurologists at the study sites of the interna-
tional consortium, GENESS (Genetic Epilepsy Studies) and then
validated byM.T.M. andA.V.D.E. The diagnosis in probands and af-
fected familymembers was based on the guidelines of theCommis-
sion on Classiﬁcation of the International League Against Epi-
lepsy.21 Each responsible person (parent or adult patient) in each
family signed an informed-consent form that was approved by
the Human Subject Protection Committee at the David Geffen
School of Medicine at the University of California, Los Angeles; or
by theNational Institute ofNeurology andNeurosurgery inMexico
City; or by the Secretary of Health of El Salvador; or by the Research
Unit at the School ofMedical Sciences at theNational Autonomous
University of Honduras. We obtained blood from 416 healthy His-
panic blood donors fromMexico. We also obtained blood samples
from 190 healthy blood donors residing in Honduras and 24 indi-
viduals considered as ‘‘married-ins’’ belonging toHonduras families
that had been recruited for genetic studies of childhood absence
epilepsy and juvenile myoclonic epilepsy. Genomic DNA was ex-
tracted from EDTA-treated blood samples with the QIAamp DNA
Blood Mini Kit (QIAGEN, Valencia, CA) and the Wizard Genomic
DNA Puriﬁcation System (Promega, Madison,WI).
Linkage Analysis
We ﬁrst used the computer-simulationmethod of Ott22,23 to assess
the strength of genetic material for linkage in families M120,
HMO10, H12, and H08, with the assumption that a dominant dis-
ease with 50% penetrance was present. We then genotyped eight
microsatellite markers located in the vicinity of the UBE3A,
GABRB3, a5 subunit gene (GABRA5), and g3 subunit gene
(GABRG3) cluster on chromosome 15q11.2-12. These markers
were selected from the OMIMdatabase and according to the report
of Glatt et al.24,25 Two-point linkage analyses were performed with
theMLINK and ILINK programs of the LINKAGE software package,
version 5.21, under the assumption of autosomal-dominant inher-
itance with 50% penetrance, with the frequency of the disease al-
lele at 0.001, phenocopy and gene-mutation rates of 1%. The allele
frequencies were estimated with the use of the Centre d’Etude du
Polymorphisme Humain (CEPH) database.
Mutation Analysis
We designed primers with the Primer 3 program to amplify the full
region spanned from the 50 UTR region to exon 3. This span starts
from 1.5 kb upstream of exon 1a to 62 bp downstream from exon
3. We also ampliﬁed all coding regions from exon 4 to exon 9, in-
cluding splice sites, and the selected regions from intron 3 and 30
UTR. For PCR reactions, the AmpliTaq Gold DNA polymerase
(Applied Biosystems, Foster City, CA) or Fast Taq polymerase
(Roche, Indianapolis, IN) was used according to manufacturer’s
instructions. Both patient and healthy-control genomic-DNA
samples served as templates for PCR ampliﬁcations. Each PCR1250 The American Journal of Human Genetics 82, 1249–1261, Junproduct of probands and controls was screened by heteroduplex
analysis with the use of denaturing high-performance liquid chro-
matography (DHPLC WAVE, Transgenomic)26,27 or directly se-
quenced with the use of ABI 3700 capillary automated-sequencing
system (Applied Biosystems, Foster City, CA). Suspected variants
were subjected to PCR at least twice and conﬁrmed by digestion
or sequences of parents.
Expression Constructs and Mutagenesis
Preparation of GABRB3 cDNAs for Expression
Full-length cDNA for human GABAA receptor b3 subunit in ex-
pression vector pCMV-SPORT 6 was obtained from American
Type Culture Collection, Manassas, VA. We isolated the complete
exon 1a and part of exon 2 by PCR, yielding onewild-type and two
mutated versions of exon 1a from probands.We then cloned them
into pCMV-SPORT after TOPO TA cloning (Invitrogen, Carlsbad,
CA). The stop codon was removed from each transcript, which
was inserted in the frame with the GFP coding sequence, in the
vector pFP-N1 to produce three versions of C-terminal GFP-tagged
GABRB3-exon 1a cDNA.
In Vitro Transcription, Translation, and Translocation
The isolated cDNA constructs from probands were cloned into
pCMV-XL5 (Origene, Rockville, MD) after TOPO TA cloning (Invi-
trogen, Carlsbad, CA). A stop codon was introduced in exon 6 after
amino acid Ile-206 by QuikChange Site-Directed Mutagenesis Kit
(Stratagene, La Jolla, CA) in order to express only the extracellular
domain of the GABRB3 protein. Each cRNA was transcribed with
theuseof themMESSAGEmMACHINET7kit (Ambion,Austin,TX).
Immunoblotting Analysis
HeLa cells were transfected with expression constructs with
Lipofectamine 2000 (Invitrogen, Carlsbad, CA), and homogenized
11–48 hr after transfection in hypotonic buffer (0.25 M sucrose,
10mMTris–HCl, 10mMNaCl, 1mMEDTA, pH 7.5) supplemented
with a mixture of protease inhibitors (Roche, Indianapolis, IN).
The lysate was centrifuged at 3300 g for 5 min to remove nuclei,
and the supernatant was used as total cytosolic-plus-membrane
Table 1. Inclusion and Exclusion Criteria of Childhood
Absence Epilepsy
Inclusion Criteria for Remitting Pyknoleptic Absence Epilepsy
(Modified from ILAE*)
Age at onset between 2 and 12 years
Brief (3-20 seconds) and frequent (>10/day) absence seizures
EEG generalized high amplitude 2.5-3.5 Hz spike (maximum 3 spikes)
and slow wave complexes lasting 3-20 seconds, spontaneously or on
hyperventilation or on photic stimulation
Normal neurological state and development
Remission of absence seizure between 10 years and 18 years of age
Exclusion Criteria for Childhood Absence Epilepsy
Myoclonic jerks prior to or during active stage of absence
Symmetric synchronous or arrhythmic myoclonus of head, trunk or limb
or a diagnosis of juvenile myoclonic epilepsy or a diagnosis of
progressive myoclonus epilepsy
Progressive neurological deterioration
*International League Against Epilepsy Commission and Terminology 1989
Classification of Epilepsies and Epileptic Syndromes
When the proband is in late childhood or early adolescence still requiring
treatment, we consider the family to have the remitting form of absence
if an affected family member has remitting form of absence.e 2008
protein fraction according to Miyawaki28 and Ganesh.29 Protein
samples were run on 10% Tris-HCl gels (BioRad, Hercules, CA)
and transferred onto a nitrocellulose ﬁlter (BioRad, Hercules, CA)
at 100 mA for one hour in transfer buffer (48 mM Tris base,
39 mM glycine, 0.037% [v/v] SDS [electrophoresis grade], 20% [v/
v] methanol, pH 8.3). The ﬁlter was incubated in blocking solution
(PBS þ 0.05% Tween 20 pH 7.4) containing 5% nonfat dry milk
powder for one hour at room temperature. The membrane was
processed through sequential incubations with primary antibody
(anti-GFP [Santa Cruz Biotechnology, Santa Cruz, CA], 1:200, dilu-
tion, monoclonal antibody against the GABAA receptor b3 subunit,
bd17 [Chemicon, Temecula, CA], 1:500, and C20 [Santa Cruz Bio-
technology, Santa Cruz, CA], 1:500) for one hour, then secondary
antibodies were added at 1:3000 for one hour. Immunoreactive
proteins on the ﬁlter were visualized by Typhoon software 9410.
Immuno-quantitation was calculated by ImageQuant 5.2.
In Vitro Transcription, Translation, and Translocation
In vitro translation and translocation were performed with the use
of the above plasmids in a coupled transcription and translocation
rabbit reticulocyte lysate system or with the use of cRNAs in nucle-
ase-treated rabbit reticulocyte lysate system (Promega, Madison,
WI), with L-[35S]methionine (GE Healthcare Bio-Sciences, Piscat-
away, NJ) in accordance with the manufacturer’s protocol. Canine
pancreatic microsomal membranes (1.8 ml) (Promega, Madison,
WI) were added directly to each reactionmedium for translocation
experiments. After incubation at 30C for 60–90 min, aliquots of
3–10 ml were diluted into 100 ml of phosphate-buffered saline
(PBS, pH 7.4) with 1 mM PMSF and kept on ice for 30 min. Micro-
somes were collected by centrifugation (20,000 3 g for one hour,
4C). The pellets were rinsed twice with 100 ml of PBS. Supernatant
proteins or the reaction without microsomes were precipitated
with 1000 ml of acetone with 10% trichloroacetic acid at 20C
overnight, centrifuged, then dissolved in sample buffer (S). For
cleaving of whole N-linked carbohydrates, each microsomal pellet
was resuspended inH2Oand then treatedwith 100 units of PNGase
F (NEB, Ipswich, MA) according to the manufacturer’s instructions
(37Cfor 3hr). Eachpellet thatwas treated (D) andornot treated (P)
with sample buffer was analyzed by SDS-PAGE on 12% or 6%–18%
Tris-HCl gels (Biorad,Hercules, CA) after denaturing at 65C for ﬁve
min with supernatant protein. After electrophoresis, gels were
soaked in 50% methanol, 7% glacial acetic acid for 30 min and
then 7% methanol, 7% glacial acetic acid and 2% glycerol for
15 min. Gels were dried and exposed to a Phosphorimager cassette
plate.Molecular weight was ascertained by the commercial protein
standard (Invitrogen, Carlsbad, CA) and the size of the supplemen-
tal control of caninemicrosomes. Immuno-quantitationwas calcu-
lated by ImageQuat 5.2. For mutations in exon 1a, the proportion
of each band density was compared with the wild-type.
Cell Culture, Transfection, and Immunomagnetic
Selection
HEK293T ﬁbroblasts were maintained in DMEM supplemented
with 10% FBS and 1% penicillin and streptomycin (all cell-culture
products from GIBCO, Carlsbad, CA) and incubated at 37C with
5% CO2/95% air. GABAA receptor subunit cDNA was inserted
into a pcDNA3.1 (a1 and g2) or pCMV (b3) promoter, and point
mutations were generated with the use of a Quikchange kit (Stra-
tagene, La Jolla, CA). For transfection, 0.3 mg of each subunit cDNA
(a1, b3, g2S) was cotransfected with 1 mg of cDNA for the pHook
antigen (Invitrogen, Carlsbad, CA) for selection. Twenty-four toThe Amthirty-six hours after transfection, positively transfected cells
were selected with the use of ferromagnetic beads in a protocol
described previously.30 After selection, cells were plated onto
35mmdishes for electrophysiological recording the following day.
Electrophysiological Recording
Single cells were chosen for recording on the basis of the presence
of two or more beads from the selection process. The external re-
cording solution consisted of (in mM): NaCl 142, KCl 8, MgCl2 6,
CaCl2 1, HEPES 10, glucose 10, pH 7.4 and 318–328mOsm. The in-
ternal recording solution consisted of (in mM): KCl 153, MgCl2 1
MgATP 2, HEPES 10, EGTA 5, pH 7.3 and 305–312 mOsm (all
reagents from Sigma-Aldrich, St. Louis, MO). Recording solutions
were designed such that the Cl reversal potential was 0 mV.
Whole-cell currents were low-pass ﬁltered at 2kHz and recorded
with the use of an Axopatch 200B Ampliﬁer (Molecular Devices,
Foster City, CA) and a Digidata 1332A (Molecular Devices) with
pClamp9.1software.Borosilicate recordingpipettes (WorldPrecision
Instruments, Philadelphia, PA) were pulled with a Sutter P-2000mi-
cropipette puller (Sutter Instruments, Novato, CA) and ﬁre-polished
with a Micro Forge (Narishige, Tokyo, Japan) to a resistance of
0.9MU–1.5 MU. Once a seal was obtained on the cell and the mem-
brane was perforated (whole-cell voltage clamp), the capacitance of
the cell was recorded from the lab-bench tool bar in pClamp9.1 (Mo-
lecular Devices). The cells were lifted off the dish and placed in front
of a glass multibarrel connected to a Piezo stepper used for rapid ap-
plicationofGABA.Perfusion fromthebarrel consistedof eitherexter-
nal solution or external solution containing 1 mM GABA (Sigma).
Open-tip exchange times between lumen of the barrel were deter-
mined by perfusion of low- and high-electrolyte solutions and were
consistently less than1ms.Foranalysisofcurrentdensity, thepipette
capacitance (13 pF) was subtracted from the cell capacitance and the
peakcurrentamplitudewasnormalized to the capacitanceof thecell.
All data was compared with the use of a Student’s paired t test, with
Welch’s correction when variances were signiﬁcantly different, and
plotted with the use of GraphPad Software (San Diego, CA).
In Silico Analysis
The genome information and homology searches were explored
with the use of the UCSC genome browser (May 2006 assembly)
and the NCBI website. GC percentage and GC-island prediction
were performed by EMBL-EBI tools (EMBOSS CpGPlot/CpGRe-
port/Isochore). The transmembraneheliceswereanalyzedbySOSUI
and TMHMM, version 2.0. The signal-peptide prediction was per-
formed by the SignalP 3.0 server, and Signal CF. N-glycosylation
and O-glycosylation sites were analyzed with NetNGlyc 1.0 and
YinOYang, respectively. The secondary-structure analysis was per-
formedbyGORIVsecondary-structure-predictionmethod.Thepre-
diction of functional effect was analyzed by the Polyphen program.
Statistical Analysis
The Fisher exact c2 test was used in comparison of the prevalence
of mutations in patients with remitting CAE versus that in con-
trols. The results of image densities were calculated and compared
by the use of a chi-square goodness-of-ﬁt test.
Results
Phenotypes
Figure 1 illustrates the pedigrees of four families (M120,
HMO10, H12, and H08) that have mutations in GABRB3.erican Journal of Human Genetics 82, 1249–1261, June 2008 1251
Table 2 summarizes the clinical characteristics of absence
seizures in probands. Table 3 identiﬁes nonproband family
members who carry GABRB3 mutations and are affected
with absences. Table 3 also lists family members with
GABRB3 mutations who are not affected by epilepsy or
absences.
Absences with eyelid myoclonias that were sensitive to
photic stimulation started at 5 and 11 years of age, respec-
tively, in probands of families M120 and H12. The proband
of family M120 only had absences and never developed
grand mal seizures. On the other hand, ﬁve separate grand
mal tonic-clonic seizures appeared at 12 years of age in the
proband of family H12. Absences without eyelid myoclo-
nias rarely appeared at 2 years of age in the proband of fam-
ily HMO10. However, they increased to more than 30
absence attacks a day between 4 and 6 years of age. Rare
sudden atonic falls appeared in early childhood, and grand
mal or myoclonic seizures never developed. The proband
of family H08 had absence without eyelid myoclonia as
the sole phenotype, and absences started at 5 years of
age. Absences and accompanying seizures disappeared
after 12 years of age in all four probands.
Three probands of families M120, HMO10, and H08
remain without seizures and without treatment. Absences
remained suppressed by valproate in the 18-year-old pro-
band of family H12. When affected by seizures, family
members most commonly had absences seizures. The fa-
ther of the proband in family M120 and the grandfather
of the proband in family HMO10 both had grand mal
tonic-clonic seizures in addition to absences. A clinically
asymptomatic sister of the proband in family H08 had
epileptiform EEG 3–4 Hz polyspike wave complexes,
Table 2. Clinical Characteristics of Pyknoleptica Absences
and Associated Seizure in Probands of Families with GABRB3
Mutations
Family
Present Age (Yrs)
and Years of
Remission
Onset
(Yrs)
Clinical
Semiology
M120 30 (18 yrs w/o
treatment, w/o seizures)
5 Staring with eyelid
myocloniasb as eyeballs
roll up. No grand mal
seizure (GM).
HMO10 14 (2 yrs w/o treatment,
w/o absence or atonic
seizures)
2 Staring with 3 Hz eye
blinks as eyeballs roll up,
Rarely absences
Absences appears at 2 yrs
of age, increased
frequency (more than 20
attacks per day) between
4 and 6 yrs.
Rare episodes of atonic
seizures with flaccid limbs
and vomiting. No GM.
H12 18 (no seizures and GM
seizures for 2 yrs but still
on treatment)
11 Staring with eyelid
myocloniab triggered by
sunlight. GM at 12 yrs.
H08 15 (5 yrs w/o treatment,
w/o absence seizures)
7 Staring as eyeballs roll up
triggered by light, No GM.
a Pyknoleptic means more than one absence seizure per day, often 20 to
200 seizures per day.
b Eyelid myoclonia consists of very rapid blinking and flickers of the eyelids
as the eyes deviate upwards.
Figure 1. Four Families with GABRB3
Mutations
Each family number is placed beside each
pedigree. Black circles or squares represent
epilepsy affected females or males. Asymp-
tomatic persons who have EEG 3 Hz diffuse
bilateral spike wave complexes or 5 to 6 Hz
sharp waves are represented by half black
circles or squares.
whereas the asymptomatic twin sister
of the proband had epileptiform EEG
bifrontal 5–6 Hz sharp waves.
Genotypes
We observed three heterozygous mis-
sense mutations, namely, P11S and
S15F in exon 1a and G32R in exon
2 (Figure 2). The P11S mutation in
exon 1a segregated with four CAE-af-
fected members of family M120. The
deceased father of the proband of
family M120 was not tested for muta-
tions. The same P11S mutation was
found in the proband and his clinically unaffected father
in family HMO10. We considered family HM010 as a sin-
gleton because we were unable to screen his CAE-affected1252 The American Journal of Human Genetics 82, 1249–1261, June 2008
Table 3. Family Members with Mutation and Absence
Family
Number
Family Members
with Mutation
Absence-Affected
Members with Mutation
Family Members Affected
with Absence
Family Members with
Mutation but No Epilepsy
Nucleotide
Change
Effect on
Protein
M120 6 4 proband, brother of proband,
two paternal male cousins
father of cousin; one brother of
two affected paternal cousins
c.31C/T Pro11Ser
HMO10 2 1 proband father of proband c.31C/T Pro11Ser
H12 3 1 proband mother of proband; half-sister of
proband (with different father)
c.44C/T Ser15Phe
H08 5 2 proband, mother of proband maternal grandmother of proband
and two sistersa of proband
c.962G/A Gly32Arg
a Two sisters with EEG abnormalities; one sister has 2–4 Hz diffuse spike- and slow-wave complexes and febrile convulsions, and the other sister has 5–6 Hz
fronto-central sharp waves.grandfather for mutations. Theoretically, family HM010
would be considered multigenerational if we had had ac-
cess to the CAE-affected grandfather. Families M120 and
HM010 are not related and reside in two separate cities of
Mexico, namely, Mexico City and Hermosillo, and have
different family names across three generations. Both
have the heterozygous c.31C / T mutation in exon 1a
at position 31 from the start codon.
The S15F mutation in exon 1a is present in the proband,
his asymptomatic mother, and his asymptomatic half
brother in family H12 fromHonduras. The G32Rmutation
in exon 2 segregated in four individuals whowere clinically
symptomatic or clinically asymptomatic with the EEG trait
only; members of two generations in family H08, also from
Honduras. P11S, S15F, and G32R mutations were not
found in 630 healthy controls fromMexico and Honduras.
Linkage Analysis
Based on quadratic interpolation, the average simulated
pooled LOD score was 1.9414 (SD 0.8848) and the maxi-
mum simulated pooled LOD score was 3.6339. The pooledThe Ammaximum two point LOD score for all 4 families (M-120,
H08, HMO10 and H12) was 1.022 for GABRB3, 2.019 for
D15S1002 and 2.305 for 85CA at theta ¼ 0 m ¼ f. 85CA
lies in 50UTR of GABRB3 (see Figure 3 and Table 4). We
obtained 0.351 for D15S122 and 3.918 for D15S1021.
In Silico Analysis
GABRB3, located on chromosome 15q11.2-q12, spans
almost 230 kb (UCSC Genome Browser, March 2006).
The mRNA of GABRB3 consists of nine exons. Two alterna-
tive ﬁrst exons, exon 1a and exon 1, encode the signal pep-
tides of GABRB3.31 Exon 1a to exon 3 spans a 1.4 kb geno-
mic region (GenBank accession number L04311) and
contains a GC-rich (55%–80%) region with high content
of CpG islands. The P11S, S15F, and G32R missense muta-
tions reside in evolutionarily conserved amino acid se-
quences of exon 1a and exon 2 (Figure 4A). All missense
mutations are predicted to have the same cleavage site as
the wild-type, cleaved between Gly22 and Ser23 amino
acids as predicted by software programs Signal P 3.1 and
Signal CF (Figure 4B). The G32R missense mutation isFigure 2. cDNA Sequencing in Each Pro-
band
Each arrow shows the location of the muta-
tion. The upper sequence represents wild-
type. The lower triplet above the arrow
represents the mutated code.erican Journal of Human Genetics 82, 1249–1261, June 2008 1253
also predicted to have the same cleavage site as the wild-
type pre-peptide, GABRB3 protein isoform 1 precursor
that is translated from the exon 1 mRNA, namely GABRB3
transcript variant 1 (NM_000814). On the basis of the
predicted cleavage site, we calculate the location of the
G32R mutation in exon 2 to occur at position 10 from
the N terminus of the mature polypeptide. This polypep-
tide is produced from the isoform 2 precursor translated
by exon 1a mRNA, namely GABRB3 transcript variant 2
(NM_021912). The secondary structure of all mutations
can be predicted to show signiﬁcant changes in secondary
structure, according to the software GOR4 IV (Figure 4C).
The software programs NetNGlyc.1.0 and YinOYang
predict with probability three N-glycosylation sites at as-
paragines and four O-glycosylation sites at serine and thre-
onine to be located in the extracellular domain (Figure 5).
Table 5 shows the potential score for the predicted N-glyco-
sylation and O-glycosylation. There is no difference in
potential for N-glycosylation between the wild-type and
missense mutations in exon 1a. However, the G32R muta-
tion has a slight but measurable lower potential at 33Asn
for an N-glycosylation site and a higher potential for an
O-glycosylation site at 23Ser (Table 5). In contrast, the
S15F mutation has only a slightly lower potential than
the wild-type and P11S for an O-glycosylation site at 23Ser.
The prediction for functional effects by mutations with
the use of the Polyphen program is applicable for the
G32R exon 2 mutation in the mature polypeptide and
the P11S exon 1a mutation but not for S15F. G32R is pre-
Figure 3. Gene and Marker Position on Chromosome 15q11-14
Figure 3 shows the relative position of markers in chr. 15q11-14.
GABRB3 (marker) is about 60kb beyond the 30 terminus of GABRB3,
and 85CA is about 50kb from exon 1a of GABRB3.24,251254 The American Journal of Human Genetics 82, 1249–1261, Junedicted to have a damaging effect on function, with
a PSIC score difference of 1.973 by GABRB3 protein iso-
form 1 (NP_000805) and 1.78 by GABRB3 protein isoform
2 (NP_068712). P11S is predicted to be benign, with a PSIC
score difference of 1.053.
Expression Study: Immunoblotting Analysis
For functional analysis, we studied ﬁrst the expression
level of full-length GABRB3-GFP fusion protein after trans-
fection into HeLa cells by immunoblotting. We used GFP
primary antibody and beta3 primary antibody to deter-
mine whether mutations in exon 1a and exon 2 had any
consequences for expression. No differences in expression
levels were observed between the mutated constructs and
the wild-type when they were harvested at earlier times;
11–12 hr after transfection (Figure 6). At expression times
of > 24 hr, the amount of each protein was variable, prob-
ably because they were digested.
In Vitro Translation and Translocation
Next, we tested whether the observed mutations inﬂu-
enced the ﬁrst steps of translation by using a cell-free
in vitro translation and translocation system. In the ab-
sence of canine pancreatic microsomes, both wild-type
and mutant cRNA (exon 1a to exon 6) were translated to
GABRB3 proteins of the same size, namely 30 kDa (Figure 7,
wild-type lane S, supernatant protein). Such proteins corre-
sponded to the preproteins of the b3 subunit before cleav-
age and contain the signal peptides and the unglycosylated
GABRB3 protein. Canine pancreatic microsomal mem-
branes (1.8 ml) (Promega, Madison, WI) were then added
directly to each reaction medium for translocation experi-
ments. After one hour of centrifugation, pellets were sepa-
rated from supernatant. The supernatant ﬂuid of all sam-
ples did not contain GABRB3 protein (not shown). The
pellets, on the other hand, contained the GABRB3 protein
that had been translocated into the microsome (Figure 7—
see translocated proteins represented as ‘‘P’’). Translocation
in the presence of 1.8 ml of canine pancreatic microsomes
precipitated all beta 3 subunit protein into the pellet.
This implied that all signal peptides were oriented toward
the membrane and that all GABRB3 protein was
Table 4. Summed Two-Point LOD Scores of Microsatellite
Markers on Chromosome 15q11-14
Microsatellite Marker
q
0 0.1 0.2 0.3 0.4
D15S1021 3.919 0.291 0.104 0.035 0.008
D15S128 0.084 0.131 0.104 0.093 0.044
D15S122 0.351 0.331 0.247 0.121 0.0054
GABRB3 1.022 0.822 0.583 0.325 0.096
85CA 2.306 1.78 1.233 0.688 0.219
D15S1002 2.019 1.535 1.038 0.554 0.16
D15S1019 0.712 0.554 0.384 0.211 0.064
D15S165 2.117 1.64 1.138 0.632 0.193
q: recombination fraction; m ¼ f.2008
Figure 4. Conserved Amino Acid Se-
quence of Exon 1a and Exon 2 of GABRB3,
Predicted Cleavage Site, and Predicted
Secondary Structure of Each Mutation
(A) Conserved amino acid sequences of
exon 1a and exon 2 of GABRB3. Each mu-
tated amino acid position is indicated by
gray shadow. 1. Homo sapiens: GABAA re-
ceptor, beta 3, (NP_068712), 2. Pongo pyg-
maeus: hypothetical protein, (CAH89717),
3. Macaca mulatta: PREDICTED GABAA
receptor, beta 3, (XP_001109060), 4. Mus
musculus: GABAA receptor, beta 3,
(NP_0010337906), 5. Rattus norvegicus:
GABAA receptor, beta 3, (EDL86448), 6.
Equus caballus: PREDICTED: similar to GA-
BAA receptor, beta 3, (XP_001493125), 7.
Canis familiaris: PREDICTED: similar to
GABAA receptor, beta 3, (XP_848482), 8.
Bos Taurus: hypothetical protein,
(NP_001092850), 9. Ornithorhynchus ana-
tinus: PREDICTED: similar to GABAA recep-
tor, beta 3, (XP_001505697), 10. Gallus
gallus: GABAA receptor, beta 3,
(NP_990677), 11. Xenopus tropicalis: Un-
known protein, (AAI36050), 12. Tetraodon
nigroviridis: unnamed protein product,
(CAG06522).
(B) Predicted cleavage site. Arrows indi-
cate each predicted cleavage site. Each
mutation is predicted to have the same
cleavage site as the wild-type exon 1a.
G32R in exon 2 is predicted to have the
same cleavage site even with exon 1 as
the wild-type. The cleavage site of exon 1
is different from the exon 1a, therefore
the N-termini differs (gray shadow).
(C) Predicted secondary structure of each
mutation.
All mutations are predicted to change sec-
ondary structures.translocated when incubating with 1.8 ml of canine pancre-
atic microsomes.
The pellet of the wild-type sample (Figure 7, lane 1)
yielded a 30 kDa protein, which was the same size as the
supernatant protein (lane 7). The pellet of the wild-type
sample, similar to translocated proteins with P11S and
S15Fmutations, also yielded bands withmolecular weights
higher than 30 kDa (seen in lanes 2 and 3). However the
image densities of bands 2 and 3 in wild-type samples
were lower than the image densities of translocated pro-
teins with P11S and S15F mutations. Figure 8 depicts re-
sults of three experiments in which we compared densities
of bands 2 and 3 inGABRB3 containing P11S and S15Fmu-
tations versus wild-type GABRB3. Densities of bands 2 and
3 in mutated GABRB3 are clearly increased compared to
bands 2 and 3 of wild-type GABRB3 (Figure 8). These larger
band products represent glycosylated forms of the GABRB3The Amprotein, and all GABRB3 proteins containing missense
mutations were hyperglycosylated compared to wild-type
GABRB3.
When samples are treated with N-glycosidase F, N-glyco-
sylation chains are eliminated and all proteins are digested
to the smaller molecular weight 28 kDa; ‘‘D’’ in Figure 7.
‘‘D’’ represents digested proteins. The 28 kDa size of the di-
gested GABRB3 protein with exon 1a mutations P11S and
S15F is the same molecular weight as the wild-type. It is
a lower molecular weight than the supernatant proteins.
However, the GABRB3 sample with exon 2 mutation
G32R has a slightly higher molecular weight than do pro-
teins in the supernatant (S), suggesting that the modiﬁca-
tion of this protein is different from that of exon 1a. This
means that missense mutations in exon 1a have excess
N-glycosylation and are able to be cleaved to the product
of the same size as that of the wild-type. The missenseerican Journal of Human Genetics 82, 1249–1261, June 2008 1255
mutation in exon 2might have a different cleavage site, no
cleavage, or normal cleavage with additional O-glycosyla-
tion. In silico analysis predicts normal cleavage and gain
of O-glycosylation at 23Ser. This observation further
suggests that the G32R mutation was subjected to more
degradation than the exon 1a mutations, perhaps due to
misfolding of GABRB3 protein containing the G32R
mutation.
Larger Current Density from Cells Expressing Wild-
Type b3-V2 Transcript than from Cells Expressing
b3-v2(P11S), b3-v2(S15F), or b3-v2(G32R) Mutations
Cells were cotransfected with equivalent amounts of cDNA
encoding for the a1, g2S, and one of the b3-v2, b3-
v2(P11S), b3-v2(S15F), or b3-v2(G32R) subunits. Saturat-
ing concentrations of GABA (1 mM) were applied to posi-
tively transfected cells for 4 s. Currents from a1b3-v2g2S
(wild-type b3 subunit with exon 1a) receptors and mutant
a1b3-v2(P11S), a1b3-v2(S15F), and a1b3-v2(G32R) recep-
tors all had a fast rate of rise, substantial multiphasic desen-
sitization, and fast deactivation upon removal of GABA
(Figure 9A). a1b3-v2g2S receptors, however, had a mean
current density (279.1 5 34.0; n ¼ 36) that was larger
than the mean current densities of a1b3-v2(P11S)g2S
(118 5 20.51; n ¼ 18, p < 0.001), a1b3-v2(S15F)g2S
(134.1 5 20.7; n ¼ 25, p < 0.001), and a1b3-
v2(G32R)g2S receptors (174.7 5 23.18; n ¼ 41, p < 0.05)
(Figure 9B). Peak-current amplitudes were reduced in
each mutant condition as well (data not shown).
Discussion
We found three missense mutations of GABRB3 (Pro11Ser,
Ser15Phe, Gly32Arg) in four out of 48 (8%) CAE-affected
patients with American Indian and Spanish European an-
cestry. Two mutations (P11S and S15F) reside in the alter-
native signal peptide, exon 1a of the GABRB3 protein. A
third mutation (G32R) is at amino acid 10 from the N ter-
minus of the mature GABRB3 protein, which in turn is
made from beta 3 isoform 2 precursor. These mutations
segregated in clinically and EEG affected individuals and
in asymptomatic persons belonging to two generations
of these four families. Vertical transmission of the GABRB3
mutations in symptomatic and asymptomatic family
members suggests a dominant trait with incomplete pene-
trance. We did not ﬁnd the samemutations in 630 healthy
ethnically and sex-matched controls.
P11S is listed as rs25409 in the SNP database of the
National Center for Biotechnology Information (NCBI),
where it is recognized as a minor allele in two out of 157
persons with autism. We do not know if these two persons
with P11S have absence epilepsy. Thirty-ﬁve percent to
sixty-ﬁve percent of patients with autism spectrum disor-
der have epileptiform EEG abnormalities, and 10% to
30% have seizures including absences.32–35 The same
NCBI database contains the results of a HapMap study in
which P11S is not found in 60 European, 44 Han Chinese,
43 Japanese, and 59 SubSaharan African persons. We did
not ﬁnd the P11S mutation in 630 controls, in sharp con-
trast to two patients with CAE (Fisher’s exact test: p ¼
0.0049). The S15F and G32R missense mutations are
both previously unreported in the NCBI databases. We
did not ﬁnd them in 416 controls from Mexico or the
214 controls from Honduras.
The GABAA receptor (GABAR) is a heteropentameric-
membrane glycoprotein that is composed of ﬁve sub-
units.36,37 The ﬁrst half of the polypeptide, which is trans-
lated from sequences of exon 2 to exon 7, forms a hydro-
philic glycosylated extracellular domain. Several parts of
Figure 5. Predicted Glycosylation Site in Exon 1a–Exon 6
of GABRB3
Bold letters without shadow show the amino acids to be dis-
placed by mutations.
Numbers show locations of amino acids.
Table 5. Predicted Glycosylation Sites and Each Potential
N-Glycosylation
Sample Position Wild-Type, P11S, S15F G32R
33 NMSF 0.5857 0.5140
105 NLTL 0.7671 0.7671
174 NCTL 0.5487 0.5487
O-Glycosylation
Sample Position Wild-Type, P11S S15F G32R
23 S 0.5166 0.4891 0.5336
157T 0.4529 0.4529 0.4529
158T 0.5198 0.5198 0.5198
201T 0.5793 0.5793 0.5793
N-glycosylation is known to occur on Asparagines (N), which is located in
the N-X-S/T stretch in which X is any amino acid except proline. The first
column has the position number of the predicted glycosylation site in
the amino acid sequences of exon 1a to exon 6 of GABRB3 (see fig. 5). Col-
umns 2 and 3 represent their potential scores, derived from the averaged
output of nine neural networks in NetNGlyc 1.0 Server. Intracellular O-gly-
cosylation is characterized by the addition of N-acetylglucosamine, in
a beta anomeric linkage (O-ß-GlcNAc), to Serine (S) and Threonine (T) res-
idues in a protein. Each number shows each position number of the pre-
dicted O-glycosylation site. The YinOYang prediction server produces
neural-network predictions for O-ß-GlcNAc attachment sites, incorporating
predicted phosphorylated sites.1256 The American Journal of Human Genetics 82, 1249–1261, June 2008
the extracellular domain are important for receptor func-
tion, including GABA and allosteric modulator binding
sites,36,37 as well as assembly signals.38 The last half of the
polypeptide is translated from sequences of the remaining
exon 7 to exon 9 and contains four hydrophobic sequences
that form transmembrane domains. So far, the sites for
binding GABA or allosteric modulators like benzodiaze-
pines have been suggested to be somewhat removed from
the N terminus in the extracellular domain, and binding
sites for general anesthetic drugs are tentatively located in
the transmembrane region.39–41 Thus, Pro11Ser and Ser15-
Phe mutations in the alternative signal peptide, exon 1a,
andGly32Argmutation in exon 2would not affect binding
sites but instead inﬂuence protein maturation, topology,
assembly, and subcellular localization of a GABAR.
In addition, two mutations in the signal peptide of
the b3-v2 subunit, P11S and S15F, caused reductions in
GABAA receptor current density when expressed as a1b3-
v2(P11S)g2S or a1b3-v2(S15F)g2S receptors and compared
to wild-type receptors (a1b3-v2g2S). Similarly, cells ex-
pressing receptors containing a b3-v2 subunit mutation
just beyond the signal peptide in exon 2, a1b3-
v2(G32R)g2S, also had smaller GABA-evoked current den-
Figure 6. Western-Blot Analysis of Whole Cell Fractions
Derived from HeLa Cell Expression 11 hr after Transfection
The GFP fusion GABRB3 protein was present at a slightly smaller
molecular weight of 80kDa which was expected.
All expression levels of plasmids with mutated sequences were the
same as the wild-type, even after normalization by Actin.The Amsity thandid cells expressingwild-type receptors. This is im-
portant because as a ligand-gated, chloride-selective ion
channel, the function of the GABAA receptor is to provide
the majority of synaptic inhibition in the central nervous
system. GABAR expression and kinetic properties are deter-
mined by the subunit combination present in the receptor.
Although there are numerous genes that encode for sub-
units and subunit subtypes of the GABAA receptor (a1-6,
b1-3, g1-3, d, 3, q, and p), the majority of the GABAA recep-
tors in the central nervous system are composed of two a,
two b, and a single g or d subunit.42,43 To date, several mu-
tations have been identiﬁed in the a1, g2, and d subunits of
the GABAA receptor associated with familial epilepsy syn-
dromes. Although these families were classiﬁed under the
generalized epilepsy with febrile seizures plus (GEFSþ) (fe-
brile and afebrile seizures) spectrum of epilepsy or juvenile
myoclonic epilepsy, all had childhood absence seizures as
a phenotype. These observations strongly suggest that GA-
BAR might be the crucial pathogenic molecule for child-
hood absence epilepsy.44 The majority of these published
GABAR mutations also cause altered subunit trafﬁcking
and, subsequently, expression of the mutated subunit,
and others alter the function of the ion channel.45
Thus, several lines of evidence favor a pathogenic role
for the P11S, S15F, and G32R mutations in absence sei-
zures. First, all three mutations reside in evolutionarily
conserved GC-rich regions and amino acid sequences of
exon 1a and exon 2 (Figure 4A). Second, in silico analysis
predicts the same cleavage sites for the wild-type as for
P11S and S15F mutations in exon 1a. In silico analysis fur-
ther predicts an alteration in secondary structure as a result
of all mutations. More interestingly, both missense muta-
tions in the signal peptide signiﬁcantly increased N-glyco-
sylation of the extracellular domain of the GABRB3 protein
in actual experiments. G32R in the N terminus of the
mature protein also increased in vitro glycosylation in ac-
tual experiments. N-glycosylation, conserved throughout
evolution,46,47 is an essential modiﬁer of protein foldingFigure 7. Increased Glycosylation of
Mutated GABRB3 Protein
Products of in vitro translocation (P) and
digestion (D) with N-glycosidase F, con-
taining the exon 1a mutations P11S and
S15F, were loaded on a 6%–18% gel (the
left gel). Similar products containing the
exon 2 mutation G32R were loaded on
a 12% gel (the right gel). The supernatant
protein (S) of only wild-type is shown (lane
7) in the 12% gel and is considered not to
be translocated to microsomes and to pres-
ent the 30kDa GABRB3 including the signal peptide. The 30 kDa supernatant protein therefore consists of untranslocated ‘‘exon 1a to exon
6.’’ Translocated proteins (P) are shown in lanes 1–3 and 8. The molecular weight of band 1 was 30 kDa. Bands 2 and 3 of both P11S and
S15F mutations in in vitro translocation (P) revealed clearly higher density than wild-type, suggesting increased glycosylation. After di-
gestion with N-glycosidase F, two smaller sized bands, 28 kDa (*), and 30 kDa (**) appeared. The 30 kDa bands represent incompletely
digested protein and 28 kDa bands represent completely digested protein. The translocated protein of G32R (P, lane 8) had only bands
larger than 30kDa, also suggesting increased glycosylation. The band of G32R has higher molecular weight than the supernatant protein
from the wild-type even after digestion.erican Journal of Human Genetics 82, 1249–1261, June 2008 1257
and transport; maintenance of cell structure; and protein
adhesion, recognition, and cell-surface trafﬁcking.47,48 In-
creased glycosylation can thus affect processing and subse-
quent assembly of GABA receptors,49 possibly resulting in
pathogenicity.50
Third, mutations in the b3-v2 subunit of the GABAA
receptor in CAE show reduced a1b3-v2(P11S)g2S, a1b3-
v2(S15F)g2S, and a1b3-v2(G32R)g2S receptor currents.
Fourth, a deletion mutation in b3 subunit of the GABAA
receptor is present in Angelman Syndrome, in which
absence-like epilepsy is present.18
The ﬁfth line of evidence supporting a pathogenic role
for the P11S, S15F, and G32Rmutations in absence seizures
concerns GABRB3 homozygous null mice that have ab-
sence-like episodes. GABRB3 heterozygous null mice like-
wise show frequent absence-like arrests of movement
with simultaneous theta bursts, suggesting an insufﬁcient
inhibition in the thalamocortical network.19,20,51 In
GABRB3-deﬁcient mice, ethosuximide stops seizures and
CBZ aggravates seizures,52 the same pharmacological char-
acteristics as those seen in human absence seizures.
GABRB3, therefore, plays an important role in the thala-
mocortical network, which underlies absence seizures.51,53
Voltage-clamp recordings of reticular neurons and ventro-
basal neurons of thalamic slices in GABRB3 homozygous
null mice show nearly abolished GABA-mediated inhibi-
tion in the reticular nucleus. GABA-mediated inhibition
was unaffected in ventrobasal relay neurons. Oscillatory
synchrony dramatically increases, showing that the recur-
rent inhibitory connections in the reticular nucleus, which
are lost in the GABRB3 null mice, actually result in de-
synchronization.54
Why do some childhood absences remit, such as those in
families M120, H12, and HMO10? The two mutations
Figure 8. Quantitation of Density of Glycosylated Bands Com-
paring Wild-Type and Exon 1a Mutations Shown in Figure 7
Bands 2 and 3 are considered to be hyperglycosylated products.
The image density of each band is the average of three experi-
ments. Since bands 2 and 3 of one sample overlapped, the sum
of bands 2 and 3 was compared. The proportion of the image
density of band 1 and the sum of bands 2 and 3 were significantly
different between the wild-type and mutations in exon 1a. (P11S,
p ¼ 0.0004, S15F, p ¼ 0.005).1258 The American Journal of Human Genetics 82, 1249–1261, June(P11S and S15F) of these three families reside in exon 1a,
located 543 base pairs upstream of exon 1. Exon 1a is richly
expressed in whole fetal human brain, including the thala-
mus,31 whereas the adult brain contains a smaller amount
of exon 1a. GABRB3 protein is highly expressed in almost
all brain regions at birth and stays constant in all regions ex-
cept the thalamus.55–58 After birth, the GABRB3 protein
decreases rapidly inmost thalamicnuclei but remains abun-
dant in the reticular thalamic nucleus, where it is one of the
main components of GABAR.57,59 However, the alternative
signal peptide coded by exon 1a is eliminated developmen-
tally in some areas like the thalamus. Perhaps as exon 1a is
eliminated developmentally, so are the absence seizures
that correlate with mutations in exon 1a.
We only investigated 7 kb (the sum of the upper region
from exon 1a, the full region from exon 1a to exon 3, all
coding region from exon 4 to exon 9 and the part of intron
3 and 30 UTR) out of 230 kb for the full GABRB3 gene, and
Figure 9. GABA-Evoked Currents of Mutations in Transfected
HEK293 Cells
The current density from cells expressing the wild-type b3-v2 tran-
script was larger than in the cells expressing the b3-v2(PS),
b3-v2(SF) or b3-v2(GR) mutations.
The current density recorded from cells expressing GABAA receptors
with b3-v2 mutations associated with CAE was reduced. A. Repre-
sentative traces of whole cell current elicited for 4 s with
1 mM GABA from cells expressing a1b3-v2g2S (WT), a1b3-
v2(P11S)g2S, a1b3-v2(S15F)g2S and a1b3-v2(G32R)g2S recep-
tors. B. Compared to cells expressing wild-type receptors (n ¼
36), the current densities of the cells expressing receptors contain-
ing the b3-v2 mutations P11S (n ¼ 18), S15F (n ¼ 25) and G32R
(n ¼ 41) were reduced (***p < 0.001, *p < 0.05).2008
more mutations could be present in the other residues of
GABRB3. Recently, the importance of epigenetic regulatory
mechanisms for the expression of GABRB3 has been em-
phasized,60 in which a heritable change of GABRB3-gene
expression could occur without a change in DNA sequence
but with a change of DNAmethylation on the CpG region.
The mutations in GABRB3 described here are associated
with a gain in glycosylation of the b3 subunit protein. Gly-
cosylation of the b3 subunit protein is known to change its
maturation and alter overall GABAR trafﬁcking to the cell
surface from the endoplasmic reticulum. We suggest that
the resulting hyperglycosylation and reduced current den-
sities of the mutated b3 subunit protein leads to absence
seizures. Our results also allow us to hypothesize that mu-
tated exon 1a leads to an abnormal isoform 2 precursor of
GABRB3 polipeptide during development. This in turn
might explain the decrease or disappearance of absence
seizures in adolescents and adults.
Supplemental Data
One ﬁgure is available at http://www.ajhg.org/.
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